Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 12Phase 4 4Phase 1/2 3Phase 1 2Phase 2/3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 13Genitourinary 3Other hematologic neoplasm 2Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 3

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Prednisolone × Genitourinary × Clear all
NCT01685268 2024-08-02

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
49 enrolled
Genitourinary

Prostatic Neoplasms

NCT01485861 2023-09-14

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Genentech, Inc.

Phase 1/2 Completed
298 enrolled 58 charts
Genitourinary

Prostatic Neoplasms

NCT00473746 2014-04-29

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

Janssen Research & Development, LLC

Phase 1/2 Completed
66 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡